ACHE and early-onset autosomal dominant Alzheimer disease: For a long time, the great potential of coumarin-triazole hybrids in anti-Alzheimer’s disease drug discovery has been well demonstrated by the target-based screening of acetylcholinesterase (AChE) (Saeedi et al., 2017; Rastegari et al., 2019), butyrylcholinesterase (BuChE) (Park et al., 2016), and β-secretase (BACE1) inhibitors (Iraji et al., 2017).